Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)
NCT ID: NCT03184402
Last Updated: 2019-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
124 participants
INTERVENTIONAL
2017-04-24
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia
NCT03024086
Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method
NCT02151708
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
NCT02567578
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
NCT02386007
A Study to Demonstrate the Efficacy and Safety of Motilitone®
NCT01817465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DWJ1252
DWJ1252
tablet
Placebo of Gasmotin
tablet
Gasmotin
Gasmotin
tablet
Placebo of DWJ1252
tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DWJ1252
tablet
Gasmotin
tablet
Placebo of Gasmotin
tablet
Placebo of DWJ1252
tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with functional dyspepsia met the ROME III criteria
Exclusion Criteria
* Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation
* Patients with history of gastrointestinal cancer
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
SMG-SNU BORAMAE MEDICAL CENTER
Role: STUDY_CHAIR
SMG-SNU Boramae Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Smg-Snu Boramae Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWJ1252003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.